OASIS Trial Progresses to Combination Therapy for Solid Tumors

Imugene Limited, an immuno-oncology firm listed on the ASX (IMU), has announced the successful completion of the initial phase of its OASIS clinical trial, which combines a CD19-expressing oncolytic virus with existing CD19-targeted treatments. The trial, which could revolutionize the treatment of solid tumors, has received a green light to proceed to the combination therapy phase after the Cohort Review Committee (CRC) found no safety issues with the onCARlytics monotherapy.
The Phase 1 study, known as OASIS, is designed for adults with advanced or metastatic solid tumors and will assess the safety and efficacy of the oncolytic virus onCARlytics, administered either via intratumoral injection or intravenous infusion, with or without the addition of blinatumomab (Blincyto®). The trial is registered at ClinicalTrials.gov with the identifier NCT06063317.
The combination therapy will involve the use of onCARlytics with the bispecific monoclonal antibody blinatumomab, which is currently approved for liquid cancers. Imugene's onCARlytics has the potential to target and destroy solid tumors that are not treatable with Blincyto® alone, marking a significant shift in cancer treatment approaches.
The OASIS trial is a dose-escalation study set to be conducted across multiple U.S. sites, with 52 patients expected to participate. Imugene's CEO, Leslie Chong, expressed optimism about the trial's progression and the potential of onCARlytics to target and eradicate solid tumors when used in combination with Blincyto®.
onCARlytics is an innovative oncolytic virus that infects tumor cells, causing them to display the CD19 protein on their surface, which can then be targeted by CD19-targeted therapies. Imugene is focused on developing novel immunotherapies to activate the immune system against cancer, with a pipeline that includes an allogeneic CAR T drug and multiple B-cell vaccine candidates, as well as oncolytic virotherapy for a range of cancers in combination with standard treatments and emerging therapies.
The company's mission is to transform cancer treatment and improve the lives of millions of patients in need of effective therapies, supported by a team of international cancer experts with a track record in developing approved cancer treatments for global markets. Imugene aims to establish its immuno-oncology therapies as foundational treatments for cancer and to lead in the expanding global market for cancer therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!